UnitedHealth Group, Eli Lilly and Company, Merck & Co., Inc., AbbVie, and Insmed are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Medical stocks within the last several days.
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Shares of UNH stock traded down $6.33 during trading hours on Friday, reaching $417.92. The company had a trading volume of 5,031,649 shares, compared to its average volume of 4,458,949. UnitedHealth Group has a 12-month low of $412.10 and a 12-month high of $630.73. The company has a market capitalization of $382.27 billion, a price-to-earnings ratio of 26.93, a PEG ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.91 and a current ratio of 0.83. The stock has a fifty day moving average of $504.95 and a 200-day moving average of $536.14.
Read Our Latest Research Report on UNH
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY stock traded up $14.54 during trading hours on Friday, hitting $874.27. The company had a trading volume of 1,521,141 shares, compared to its average volume of 3,428,521. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company's fifty day moving average is $827.14 and its 200 day moving average is $818.81. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The stock has a market capitalization of $828.96 billion, a PE ratio of 74.51, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.
Read Our Latest Research Report on LLY
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of MRK stock traded up $2.19 on Friday, hitting $82.03. The stock had a trading volume of 14,146,380 shares, compared to its average volume of 11,842,810. The company's 50 day moving average price is $87.06 and its 200-day moving average price is $95.41. Merck & Co., Inc. has a 1 year low of $75.93 and a 1 year high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The firm has a market capitalization of $206.87 billion, a P/E ratio of 12.15, a P/E/G ratio of 0.77 and a beta of 0.40.
Read Our Latest Research Report on MRK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE ABBV traded up $4.74 during midday trading on Friday, hitting $185.11. The company's stock had a trading volume of 5,909,289 shares, compared to its average volume of 6,044,333. The firm has a market capitalization of $327.45 billion, a price-to-earnings ratio of 77.06, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The business's fifty day simple moving average is $197.05 and its two-hundred day simple moving average is $187.28.
Read Our Latest Research Report on ABBV
Insmed (INSM)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Shares of Insmed stock traded up $0.47 during trading hours on Friday, reaching $69.43. 11,268,730 shares of the company were exchanged, compared to its average volume of 2,289,214. The firm has a market cap of $12.62 billion, a PE ratio of -12.42 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed has a 1 year low of $21.92 and a 1 year high of $84.91. The stock's fifty day moving average is $74.61 and its 200 day moving average is $73.55.
Read Our Latest Research Report on INSM
Read More
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
